Cohance Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cohance Lifesciences (formerly Suven Pharmaceuticals) has informed the stock exchanges about a Board Meeting scheduled for Wednesday, August 13, 2025. The board will consider and approve the Unaudited Financial Results (both Standalone and Consolidated) for the quarter ending June 30, 2025, which is the first quarter of FY26. In line with SEBI's Insider Trading Regulations, the trading window for dealing in the company's shares will be closed from July 1, 2025, to August 15, 2025, to prevent insider trading ahead of the results announcement. No financial numbers or business details have been disclosed in this filing.
This is a routine regulatory intimation and has no direct impact on the stock price. Investors should note the trading window closure, which means insiders cannot trade during this period, and await the Q1 FY26 results on August 13 for actual performance insights.